Date:3/12/2009

se will be expanded, which may not occur due to a number of factors including potential lack of demand for Helix's shares, the fact that Helix's shares will be "penny stock" and subject to certain restrictions, and the state of the financial and stock markets generally; uncertainty whether the Company's products under development, including Topical Interferon Alpha-2b and L-DOS47 will be successfully developed and commercialized as a drug or at all; the need for additional clinical trials, the occurrence and success of which cannot be assured; product liability and insurance risks; research and development risks; the risk of technical obsolescence; the need for further regulatory approvals, which may not be obtained in a timely matter or at all; intellectual property risks; marketing/manufacturing and partnership/strategic alliance risks; the effect of competition; uncertainty of the size and existence of a market opportunity for Helix's products; as well as a description of other risks and uncertainties affecting Helix and its business, as contained in news releases and filings with the securities regulatory authorities, including its latest Annual Information Form, at www.sedar.com and Form 20-F at www.sec.gov/edgar.shtml, any of which could cause actual results to vary materially from current results or Helix's anticipated future results. Forward-looking statements and information are based on the beliefs, assumptions, opinions and expectations of Helix's management at the time they are made, and Helix does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions or expectations, or other circumstances change, except as required by law.

'/>"/>

SOURCE Helix BioPharma Corp. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. London-Based Double Helix Consulting Launches US Division for Strategic Pricing, Reimbursement and Market Access Solutions
2. Helix BioPharma Announces Q1 2009 Financial Results
3. Helix BioPharma Files Form 20-F Registration Statement With the U.S. Securities and Exchange Commission
4. Helix BioPharma Corp. Announces Fiscal 2008 Results
5. Helix Biopharma Closes $11.4 Million Private Placement
6. Helix BioPharma Announces $11.4 Million Private Placement
7. Helix BioPharma to Present L-DOS47 Research Findings at the National Research Council of Canadas Eighth Annual General Meeting of the Genomics and Health Initiative in Saskatoon, Canada
8. Sigma-Aldrich Announces Collaboration With Metahelix Life Sciences
9. Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008
10. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
11. Helix BioPharma reports Q2 2008 highlights, financial results